NICE backs Cimzia for psoriasis, but rejects Ilumetri
Cost watchdog the National Institute for Health and Care Excellence has backed NHS funding for UCB’s Cimzia as a treatment for psoriasis, but is not recommending Almirall’s Ilumetri.
Read More
Tag: tildrakizumab
Almirall steps into psoriasis market with Ilumetri approval
The European Commission has approved Almirall’s Ilumetri for moderate-to-severe chronic plaque psoriasis.
Read More
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
- Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
- ErVimmune raises 17m euros in funding to develop cancer vaccine
